June 17, 2026

Indeterminate Thyroid Nodule Size May Predict RFA Success

In a functionally screened cohort, there was an 85% likelihood of being free of local treatment failure at 3 years, with outcomes favoring nodules smaller than 3 cm.

Conexiant

June 15, 2026

FDA Approves Low-Dose Macrocyclic Contrast Agent for MRI

The macrocyclic gadolinium-based contrast agent has a recommended dose of 0.01 mmol/kg actual body weight.

Conexiant

June 11, 2026

Medical Oddities: The Economics of Shut-Eye

Sleep became a commodity, tea became a therapy, and cats got a reprieve this week.

Conexiant

June 02, 2026

Consensus Guidance May Improve Sinonasal Mass Outcomes

Multidisciplinary recommendations emphasize biopsy technique, imaging, and pathology review in patients with suspected sinonasal malignancy.

Conexiant

May 15, 2026

Could Micro-CT Improve Tooth Fragment Matching?

Researchers achieved sub-100-µm precision when digitally reassociating fragmented teeth in a controlled forensic model.

Conexiant

May 14, 2026

AAE Revises Dental Trauma Guidance

Recommendations outline splinting, replantation timing, imaging, and long-term surveillance strategies for permanent tooth injuries.

Conexiant

May 11, 2026

The Bill Nobody's Discussing in the Exam Room

Head and neck cancer costs are crushing patients — yet cost discussions remain uncommon in clinical care.

Conexiant

May 08, 2026

Reduced-Dose Radiation Shows Durable Control

Single-arm cohort findings contrast with interim results from NRG-HN005, underscoring ongoing uncertainty around treatment deintensification.

Conexiant

May 06, 2026

Distress Screening in a Cancer Survivorship Clinic: Impact on Psychosocial Referrals

This quality improvement project found that using a distress screening tool for head and neck cancer patients who were 2 or more years post-treatment led to an increased number of referrals for psychosocial needs.

Jadpro

April 23, 2026

FDA Grants Accelerated Approval for OTOF Gene Therapy

A one-time intracochlear gene therapy improved hearing outcomes in patients with OTOF-related sensorineural hearing loss in the phase 1/2 CHORD trial.

Conexiant